Jitesh Kawedia
Overview
Explore the profile of Jitesh Kawedia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
71
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nash A, Dinh C, Kawedia J, McCall D, Weinman S, Garcia M, et al.
Pediatr Blood Cancer
. 2025 Jan;
72(3):e31519.
PMID: 39757556
No abstract available.
2.
Badgwell B, Ikoma N, Blum M, Wang X, Estrella J, Liu X, et al.
Cancer
. 2024 Sep;
131(1):e35566.
PMID: 39287936
Background: The purpose of this phase 1 trial was to evaluate the safety and toxicity of repeated normothermic intraperitoneal paclitaxel (PTX) for patients with gastric cancer metastatic to the peritoneum....
3.
Ragoonanan D, Abdel-Azim H, Sharma A, Bhar S, McArthur J, Madden R, et al.
Lancet Reg Health Am
. 2024 Apr;
33:100728.
PMID: 38616918
Background: Sinusoidal obstruction syndrome is a potentially fatal complication following hematopoietic cell transplantation, high-intensity chemotherapies and increasingly seen with calicheamicin based leukemia therapies. Paediatric specific European Society for Blood and...
4.
Mazumdar A, Tahaney W, Hill J, Zhang Y, Ramachandran S, Kawedia J, et al.
Cancer Prev Res (Phila)
. 2022 Aug;
15(12):791-802.
PMID: 35981902
Our results show that everolimus delays mammary tumor formation in multiple mouse models, suggesting that mTOR inhibitors will be useful for the prevention of ER-negative and triple-negative breast cancer in...
5.
Popat U, Andersson B, Bassett R, Kawedia J, Valdez B, Alousi A, et al.
Haematologica
. 2022 Jun;
107(10):2496-2500.
PMID: 35770531
No abstract available.
6.
Alatrash G, Saberian C, Bassett R, Thall P, Ledesma C, Lu Y, et al.
Transplant Cell Ther
. 2022 May;
28(8):501.e1-501.e7.
PMID: 35618218
Conditioning regimens play a major role in determining disease outcomes following allogeneic hematopoietic stem cell transplantation (allo-HSCT). The use of i.v. busulfan (Bu) as part of conditioning chemotherapy has been...
7.
Andersson B, Thall P, Ma J, Valdez B, Bassett Jr R, Chen J, et al.
Bone Marrow Transplant
. 2022 May;
57(8):1295-1303.
PMID: 35610308
Pretransplant conditioning with Fludarabine (Flu)-Busulfan (Bu) is safe, but clofarabine (Clo) has improved antileukemic activity. Hypothesis: Flu+Clo-Bu (FCB) yields superior progression-free survival (PFS) after allogeneic transplantation. We randomized 250 AML/MDS...
8.
Gibson A, Hernandez C, Tejada F, Kawedia J, Rytting M, Cuglievan B
Paediatr Drugs
. 2021 Aug;
23(5):457-463.
PMID: 34351604
Asparaginase therapy is a vital agent in the treatment of acute lymphoblastic leukemia (ALL), with increasing evidence of its high importance in high-risk ALL populations. However, despite the clear clinical...
9.
Mehta R, Bassett R, Chen J, Valdez B, Kawedia J, Alousi A, et al.
Transplant Cell Ther
. 2021 Jul;
27(11):913.e1-913.e12.
PMID: 34329753
Compared to reduced-intensity conditioning regimen, myeloablative conditioning (MAC) for hematopoietic stem cell transplantation (HCT) reduces relapse but is avoided in older patients because of higher non-relapse mortality (NRM). To meet...
10.
Popat U, Mehta R, Bassett R, Chen J, Valdez B, Kawedia J, et al.
Lancet Haematol
. 2018 Nov;
5(11):e532-e542.
PMID: 30389035
Background: Haemopoietic stem-cell transplantation (HCT) conditioning regimens that can reduce risk of relapse without increasing non-relapse mortality are needed. We aimed to test the safety of timed-sequential delivery of low-dose...